INDICLOR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDICLOR is an injectable diagnostic or imaging agent developed by GE HealthCare, approved in 1992. The specific indication and mechanism of action are not publicly detailed in available sources. It represents a legacy injectable product from the diagnostic/imaging therapeutic area.
LOE Approaching
With lifecycle stage approaching loss of exclusivity and minimal current linked job positions, the brand team is likely in maintenance-to-transition mode with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE lifecycle, INDICLOR offers minimal active career development opportunities. This product is best suited for professionals seeking stability in a mature, maintenance-focused role rather than growth or innovation-driven positions.
Product Manager (Diagnostics)Sales Representative
Worked on INDICLOR at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.